Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Thursday. They presently have a $20.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 120.99% from the stock’s previous close.
A number of other analysts have also issued reports on ABEO. Maxim Group set a $14.00 price target on Abeona Therapeutics and gave the company a “buy” rating in a report on Saturday, May 13th. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price target on shares of Abeona Therapeutics in a report on Tuesday, June 6th. BidaskClub lowered Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 27th. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Abeona Therapeutics in a report on Thursday, June 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Abeona Therapeutics has a consensus rating of “Buy” and an average price target of $17.86.
Abeona Therapeutics (NASDAQ:ABEO) opened at 9.05 on Thursday. Abeona Therapeutics has a 52-week low of $3.90 and a 52-week high of $10.26. The company’s market capitalization is $364.60 million. The firm has a 50-day moving average price of $8.52 and a 200 day moving average price of $6.21.
Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.07. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.21 million. On average, analysts predict that Abeona Therapeutics will post ($0.67) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/26/hc-wainwright-reiterates-buy-rating-for-abeona-therapeutics-inc-abeo.html.
Hedge funds have recently made changes to their positions in the stock. State of Wisconsin Investment Board acquired a new position in shares of Abeona Therapeutics during the second quarter worth approximately $122,000. Private Advisor Group LLC increased its position in shares of Abeona Therapeutics by 50.0% in the first quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 6,999 shares during the period. Family Management Corp acquired a new position in shares of Abeona Therapeutics during the first quarter worth approximately $120,000. Rhumbline Advisers acquired a new position in shares of Abeona Therapeutics during the second quarter worth approximately $190,000. Finally, Segantii Capital Management Ltd increased its position in shares of Abeona Therapeutics by 564.6% in the first quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 28,794 shares during the period. Hedge funds and other institutional investors own 36.15% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
